

# Arrhythmias are caused by defects in signal formation and/or conduction

## ABNORMAL FORMATION

- Abnormal automaticity of SA/AV cells (altered rate)
- Abnormal automaticity of cardiac muscle cells (premature beats)

Defects in Automaticity

## DECREASE AUTOMATICITY

① Increase threshold potential

**Class I: Na<sup>+</sup> channel blockers**

IA - procainamide

IB - lidocaine

IC - flecainide, propafenone

② Decrease phase 4 slope

**Class II: β antagonists**

Atenolol

Metoprolol

③ Increase AP duration

**Class III: K<sup>+</sup> channel blockers**

Amiodarone - has extra-cardiac toxicities

Dofetilide

Ibutilide

- skin/mucosal discoloration
- hypo/hyperthyroidism
- hepatic/pulm toxicities
- peripheral neuropathy

**Class IA: Na<sup>+</sup> channel blockers**

Procainamide also K<sup>+</sup> channel blocker

④ Slow SA/AV node depolarization

**Class IV: Ca<sup>2+</sup> channel blockers**

Diltiazem only non-dihydropyridines

Verapamil

- act on cardiac tissue AND vascular smooth muscle

⑤ Increase max diastolic potential

**Other - nucleoside**

Adenosine

- promotes K<sup>+</sup> efflux

## ABNORMAL CONDUCTION

Reentry Rhythms

- ① tissue damage
- ② uni-directional block
- ③ time for retrograde signal > refractory period

AV blocks

Can't treat

Structural defects creating reentry circuits

**INCREASE APD + RP**

**IA + III** **DECREASE CONDUCTION VELOCITY**

Disrupt timing of reentry circuit

**SA/AV** Ca<sup>2+</sup> dependent depolarization **CM** Na<sup>+</sup> dependent depolarization

AV blocking drugs

"Nodal agents"

**Class I: Na<sup>+</sup> channel blocker**

Procainamide - mod.

Lidocaine - weak

Flecainide  
Propafenone } Strong

Slow depolarization of non-nodal tissue and slow conduction velocity

**Class II: β blockers**

Atenolol  
Metoprolol

reduce sympathetic stimulation of CM depolarization → ↓ conduction velocity

**Class IV: Ca<sup>2+</sup> channel blockers**

Diltiazem  
Verapamil

Slow Ca<sup>2+</sup> dependent phase 2 depolarization of CMs →

↓ conduction velocity

**Class II: β antagonists**

Atenolol  
Metoprolol

Slow Na<sup>+</sup> influx • reduce phase 4 slope

**Class IV: Ca<sup>2+</sup> channel blockers**

Diltiazem  
Verapamil

Slow Ca<sup>2+</sup> influx

**Adenosine**

Inhibits Ca<sup>2+</sup> channel opening

Slow conduction through AV node

**DIGOXIN** slows aberrant depolarization wave reaching AV node.

• doesn't actually block AV node but prevents signal from reaching it.

**Inhibits Na<sup>+</sup>/K<sup>+</sup> ATPase**


↳ buildup of Na<sup>+</sup> in cell → more pumped out Na<sup>+</sup>/Ca<sup>2+</sup> exchanger

↳ ↑ Ca<sup>2+</sup> entering cell

↑ inotropy in treating HF and lengthens myocardial AP.

# DECREASE AUTOMATICITY


## ① Increase depolarization threshold



Block  $\text{Na}^+$  channels  $\rightarrow$  increased threshold

- Delays second beat by slowing the resetting of  $\text{Na}^+$  channels after an AP.
- By binding open/inactive states, they are selective for rapidly depolarizing tissues

## ② Decrease phase 4 slope



Block  $\text{B}_1$  receptor  $\rightarrow$  slows HR

- takes longer to reach threshold potential
- prevents arrhythmia and decreases blood pressure.

## ③ Increase action potential duration



Block  $\text{K}^+$  channels  $\rightarrow$  extend plateau and slow repolarization

Toxicities: prolonged AP  $\rightarrow$  prolonged QT  $\rightarrow$  Torsades

## ④ slow depolarization in SA/AV node cells.

$\text{Ca}^{2+}$  is responsible for rapid depolarization in SA/AV nodes.


Block  $\text{Ca}^{2+}$  channels  $\rightarrow$  slows abnormal impulses

## ⑤ Increase maximum diastolic potential



Make the interior of the cell more negative between action potentials.

- hyperpolarize muscle cell by promoting  $\text{K}^+$  efflux  $\rightarrow$  increases diastolic membrane potential.



# ATRIAL FIBRILLATION irregular and erratic rhythm

Increases risk of clotting events.

◦ Atria beating irregularly → blood pools → clots in atria

Anti-Clotting Drugs - usually required in Afib patients

- ① Dabigatran : factor IIa (thrombin) inhibitor.
- ② Apixaban : factor II inhibitor
- ③ Rivaroxaban : factor II inhibitor
- ④ warfarin / coumadin : vitamin K inhibitor. Indirect-acting.

## RATE VS. RHYTHM CONTROL

Afib can produce ventricular tachycardia/fibrillation.

Rhythm Control : use of drugs to restore normal sinus rhythm.

**Amiodarone** restores NSR by interrupting the atrial reentry circuit by increasing myocyte refractory period (**K<sup>+</sup> channel blockade**)


Rate Control : use of drugs to slow ventricular rate in response to Afib

**AV blocking drugs** prevent signal from passing through AV node.

- **β-antagonists** (**Amiodarone**)
- **Ca<sup>2+</sup> channel blockers**
- **Adenosine** - has β-blocking activity and can be AV blocking agent.
- **Digoxin** - slows aberrant depolarization wave reaching AV node

Treatment of Afib is complicated by:

### drug-drug interactions



Amiodarone also blocks excretion of **digoxin**.

### concomitant conditions

HF	HTN	Afib
b blocker	b blocker	b blocker
ACEi	ACEi	<b>Digoxin</b>
Diuretic	Diuretic	<b>Amiodarone</b>
<b>Digoxin</b>		<b>Non-DHP CCB</b>
<b>worsened by:</b>		<b>Warfarin</b>
<b>b blocker + non-dhp CCB</b>		
	<b>b blockers worsen:</b>	
	diabetes, asthma, COPD	